DTaP@-IPV-Hib-HepB administered concomitantly with PCV@ or @ month apart at @ months of age following the infant series was well-tolerated and elicited antibody responses to all vaccine antigens , with no significant interference from concomitant PCV@ administration ( clinicaltrials.gov registration number NCT@ ) .